Migraine – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Prophylaxis) US

According to Clarivate epidemiology, more than 30 million people in the United States suffer from migraines. Despite being underused, migraine prophylaxis is a core treatment approach to reduce the frequency, severity, and duration of migraines. Prescription options include a diverse mix of on- and off-label oral drugs, AbbVie / Allergan’s Botox, and multiple anti-CGRP monoclonal antibodies (MAbs). Prophylaxis is both individualized and dynamic as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as the prophylactic therapy market prepares for the entry of new oral CGRP receptor antagonists—namely, Biohaven’s Nurtec ODT and AbbVie / Allergan’s atogepant.

QUESTIONS ANSWERED

  • What patient shares do oral standards of care and invasive brands garner by line of therapy in migraine patients initiating prophylaxis? What are the quarterly trends in prescribing among recently treated and prophylactically naive migraine patients?
  • What is the dynamic between anti-CGRP MAbs? How has Lundbeck’s Vyepti been integrated into the treatment algorithm, and what claims does it capture?
  • What percentage of prophylactically naive migraine patients began drug therapy during our two-year prescription-tracking period? What percentage of patients progress to later lines of therapy, and how quickly do they progress?
  • What percentage of migraine patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among prophylactically treated migraine patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Amgen / Novartis, Eli Lilly, Teva, Lundbeck, AbbVie / Allergan, Supernus Pharmaceuticals, Upsher-Smith, and Janssen-Cilag

Key drugs: Aimovig, Emgality, Ajovy, Vyepti, Botox, Trokendi XR, Qudexy XR, topiramate IR/XR, propranolol, amitriptyline, and verapamil

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Migraine - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Prophylaxis) US
    • Treatment Algorithms CDA Migraine (Prophylaxis) US May 2021
    • Treatment Algorithms CDA Migraine (Prophylaxis) US 2021 Dashboard

launch Related Market Assessment Reports